Dette VACC patentet og det nye NAc patentet gjenspeiles ikke på noen som helst måte i dagens aksjekurs - Da dette er en unik teknologi som ingen andre enn PCIB har.
21 January 2020 PCIB announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fima Vacc in combination with cytokines.
This granted US patent secure protection until 2035 and this patent application is still pending in Europe and key Asian markets.
Cytokines are small proteins that are involved in cell signaling, and that are very important in the immune system, modulating both cell-based and humoral immune responses.
The combination of cytokines with PCI Biotechs vaccine technology, fima Vacc , has been shown to be effective for enhancing cellular immune responses that are important for the effect of therapeutic vaccines.
The now granted US patent gives broad coverage for the combination of various cytokines with the fima Vacc technology.
There are many vaccines under development utilising cytokines to elicit immune responses. The US patent granted today is important for PCI Biotechs development strategy, as it supplements our ability to generate an internal future vaccine pipeline, in addition to bringing value for the fima Vacc technology in partnering efforts, said Per Walday, CEO of PCI Biotech.
Denne nye vaksineteknologien bruker en unik virkningsmåte, utløst endosomal frigjøring av antigener, for å styrke den essensielle cytotoksiske effekten av terapeutiske kreftvaksiner og fungerer i synergi med flere andre moderne vaksinasjonsteknologier.
Underliggende verdier av disse patentene kan fort bli betydelige…!!
